Security key
140755307
Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD)
CUSIP: 140755307
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 40
- Total 13F value
- $76
- Share change
- -49
- SEC-reported price per share
- $1.90
- Number of holders
- 1
- Value change
- -$93
- Number of sells
- 1
- Shares outstanding
- 9,470,889
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
1
Top holders
1
TVRD full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Tvardi Therapeutics, Inc. SEC filings
Tvardi Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 140755307
Recent filing periods:
Ownership snapshot
Top reported holders of TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Sporos Bioventures LLC
Disclosed value leader
Sporos Bioventures LLC
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 9%
13D/G row: Sporos Bioventures LLC
Showing 1-6 of 15 holder rows.
Quick read
Sporos Bioventures LLC leads the comparable SEC ownership view at 9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Sporos Bioventures LLC's linked filing trail.
Comparable ownership
Top 5
Sporos Bioventures LLC
9%
Solas Tvardi Sidecar LLC
8.1%
Slate Path Capital LP
7.5%
David J. Tweardy
7%
Ronald A. DePinho
4.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Sporos Bioventures LLC |
13D/G
|
9%
|
$19,544,812
837,636 shares
|
$0 | 15 Apr 2025 |
| Solas Tvardi Sidecar LLC |
13D/G
|
8.1%
|
$4,050,047
761,287 shares
|
$0 | 15 Apr 2025 |
| Slate Path Capital LP |
13D/G
13F
Company
|
7.5%
|
$19,257,627
704,118 shares
|
$0 | 30 Jun 2025 |
| David J. Tweardy |
13D/G
|
7%
|
$3,470,757
652,398 shares
|
$0 | 15 Apr 2025 |
| Ronald A. DePinho |
13D/G
|
4.5%
|
$1,939,164
426,190 shares
|
$0 | 31 Dec 2025 |
| Samuel D. Tweardy |
13D/G
|
3.4%
|
$7,365,343
315,658 shares
|
-$14,730,686 | 07 Jul 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
40
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
66
Q2 2026 holders
1
Holder diff
-65
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend